Comparison of different approaches for assessment of HER2 expression on protein and mRNA level: prediction of chemotherapy response in the neoadjuvant GeparTrio trial (NCT00544765)

[1]  C. Denkert,et al.  Effect of neoadjuvant anthracycline–taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study , 2010, Breast Cancer Research and Treatment.

[2]  M. Untch,et al.  Reliability of human epidermal growth factor receptor 2 immunohistochemistry in breast core needle biopsies. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  R. Aft,et al.  Predictors of complete pathological response after neoadjuvant systemic therapy for breast cancer. , 2009, American journal of surgery.

[4]  W. Weichert,et al.  Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy , 2009, Breast Cancer Research.

[5]  Uwe Rogel,et al.  RNA extraction from archival formalin-fixed paraffin-embedded tissue: a comparison of manual, semiautomated, and fully automated purification methods. , 2009, Clinical chemistry.

[6]  C. Denkert,et al.  Neoadjuvant chemotherapy in operable breast cancer with docetaxel, doxorubicin, and cyclophosphamide (TAC) or TAC followed by vinorelbine and capecitabine (NX): Final results and analysis of markers predicting response to treatment. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  G. Kristiansen,et al.  Quantitative determination of predictive cancer biomarkers in formalin-fixed, paraffin-embedded tissue using a new, fully automated method for RNA isolation. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  A. Tutt,et al.  A single-tube quantitative assay for mRNA levels of hormonal and growth factor receptors in breast cancer specimens. , 2009, The Journal of molecular diagnostics : JMD.

[9]  Robin L. Jones,et al.  Relationship between oestrogen receptor status and proliferation in predicting response and long-term outcome to neoadjuvant chemotherapy for breast cancer , 2009, Breast Cancer Research and Treatment.

[10]  M. Dimopoulos,et al.  Evaluation of the prognostic and predictive value of HER family mRNA expression in high-risk early breast cancer: A Hellenic Cooperative Oncology Group (HeCOG) study , 2008, British Journal of Cancer.

[11]  A. Gown.  Current issues in ER and HER2 testing by IHC in breast cancer , 2008, Modern Pathology.

[12]  S. Loibl,et al.  Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial. , 2008, Journal of the National Cancer Institute.

[13]  S. Loibl,et al.  Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio study. , 2008, Journal of the National Cancer Institute.

[14]  K. Hess,et al.  Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  S. Paik,et al.  Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  A. Chaudhuri,et al.  HER2 Status and Benefit from Adjuvant Trastuzumab in Breast Cancer , 2008 .

[17]  G. Hortobagyi,et al.  HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer , 2008, Breast Cancer Research and Treatment.

[18]  A. Schneeweiss,et al.  Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  T. Karn,et al.  The erbB2+ cluster of the intrinsic gene set predicts tumor response of breast cancer patients receiving neoadjuvant chemotherapy with docetaxel, doxorubicin and cyclophosphamide within the GEPARTRIO trial. , 2007, Breast.

[20]  C. Perou,et al.  The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes , 2007, Clinical Cancer Research.

[21]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. , 2006, Archives of pathology & laboratory medicine.

[22]  Robin L. Jones,et al.  Topoisomerase II alpha amplification may predict benefit from adjuvant anthracyclines in HER2 positive early breast cancer , 2007, Breast Cancer Research and Treatment.

[23]  D. Hayes,et al.  New guidelines for reporting of tumor marker studies in breast cancer research and treatment: REMARK , 2006, Breast Cancer Research and Treatment.

[24]  Andreas Makris,et al.  Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  G. Hortobagyi,et al.  Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  D. Berry.  Chemotherapy is More Effective in Patients With Breast Cancer Not Expressing Steroid Hormone Receptors: A Study of Preoperative Treatment , 2006 .

[27]  Berthold Streubel,et al.  Expression of HER2 and the Coamplified Genes GRB7 and MLN64 in Human Breast Cancer: Quantitative Real-time Reverse Transcription-PCR as a Diagnostic Alternative to Immunohistochemistry and Fluorescence In situ Hybridization , 2005, Clinical Cancer Research.

[28]  W. Sauerbrei,et al.  Reporting recommendations for tumor marker prognostic studies (REMARK). , 2005, Journal of the National Cancer Institute.

[29]  Roman Rouzier,et al.  Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy , 2005, Clinical Cancer Research.

[30]  A. Luini,et al.  Chemotherapy Is More Effective in Patients with Breast Cancer Not Expressing Steroid Hormone Receptors , 2004, Clinical Cancer Research.

[31]  D. Birnbaum,et al.  Comparative multi‐methodological measurement of ERBB2 status in breast cancer , 2004, The Journal of pathology.

[32]  A. Gown,et al.  Accuracy and precision in HER2/neu testing in breast cancer: are we there yet? , 2004, Human pathology.

[33]  Jinha M. Park,et al.  Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  John J Spinelli,et al.  HER-2/neu in Breast Cancer: Interobserver Variability and Performance of Immunohistochemistry with 4 Antibodies Compared with Fluorescent In Situ Hybridization , 2001, Modern Pathology.

[35]  M. Untch,et al.  Her-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.